Expert opinion on current therapies for nonalcoholic fatty liver disease

Bibliography

• Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-50
   PubMed Web of Science ®Google Scholar
• Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis 2008;28:386-95
   PubMed Web of Science ®Google Scholar
• Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010;7:195-203
   PubMed Web of Science ®Google Scholar
• Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010;28:155-61
   PubMed Web of Science ®Google Scholar
• Alisi A, Manco M, Vania A, Nobili V. Pediatric nonalcoholic fatty liver disease in 2009. J Pediatr 2009;155:469-74
   PubMed Web of Science ®Google Scholar
• Weston SR, Leyden W, Murphy R, Racial and ethnic distribution of non-alcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005;41:372-9
   PubMed Web of Science ®Google Scholar
• Browning JD, Szczepaniak LS, Dobbins R, Prevalence of hepatic steatosis in an urban population in United States: impact of ethnicity. Hepatology 2004;40:1387-95
   PubMed Web of Science ®Google Scholar
• Schwimmer JB, Celedon MA, Lavine JE, Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009;136:1585-92
   PubMed Web of Science ®Google Scholar
• Alisi A, Cianfarani S, Manco M, Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment. Ann Med 2011; published online 28 February 2011; doi:10.3109/07853890.2010.547869
   PubMed Web of Science ®Google Scholar
• Perseghin G. The role of non-alcoholic fatty liver disease in cardiovascular disease. Dig Dis 2010;28:210-13
   PubMed Web of Science ®Google Scholar
• Ratziu V, Bellentani S, Cortez-Pinto H, A position statement on NAFLD/NASH based on EASL 2009 special conference. J Hepatol 2010;53:372-84
   PubMed Web of Science ®Google Scholar
• Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008;49:608-12
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Franzen LE, Mathiens UL, Long-term follow up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73
   PubMed Web of Science ®Google Scholar
• Adams LA, Waters OR, Knuiman MW, NAFLD as a risk factor for development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009;104:861-7
   PubMed Web of Science ®Google Scholar
• Feldstein A, Charatcharoenwitthaya P, Treeprasertsuk S, The natural history of nonalcoholic fatty liver disease in children: a follow-up study for up to 20-years. Gut 2009;58:1538-44
   PubMed Web of Science ®Google Scholar
• Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007;11:1-16
   PubMedGoogle Scholar
• Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51:1820-32
   PubMed Web of Science ®Google Scholar
• Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Ann Rev Pathol 2010;5:145-71
   PubMed Web of Science ®Google Scholar
• Mahli H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008;28:360-9
   PubMed Web of Science ®Google Scholar
• Lockman KA, Nyirenda MJ. Interrelationships between hepatic fat and insulin resistance in non-alcoholic fatty liver disease. Curr Diabetes Rev 2010;6:341-7
   PubMedGoogle Scholar
• Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 2010;55:560-78
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010;52:1836-46
   PubMed Web of Science ®Google Scholar
• Federico A, D'Aiuto E, Borriello F, Fat: a matter of disturbance for the immune system. World J Gastroenterol 2010;16:4762-72
   Google Scholar
• Estep JM, Baranova A, Hossain N, Expression of cytokine signalling genes in morbidly obese patients with non-alcoholic steatohepatitis and hepatic fibrosis. Obes Surg 2009;19:617-24
   PubMed Web of Science ®Google Scholar
• Feldstein A. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis 2010;30:391-401
   PubMed Web of Science ®Google Scholar
• Romeo S, Kozlitina J, Xing C, Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-5
   PubMed Web of Science ®Google Scholar
• Petersen KF, Dufour S, Hariri A, Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 2010;285:6706-15
   Google Scholar
• Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 2010;11:430-45
   PubMed Web of Science ®Google Scholar
• Johnson N, George J. Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology 2010;52:370-81
   PubMed Web of Science ®Google Scholar
• Hickman IJ, Jonsonn JR, Prins JB, Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin and quality of life. Gut 2004;53:413-19
   PubMed Web of Science ®Google Scholar
• Nobili V, Manco M, Devito R, Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008;48:119-28
   PubMed Web of Science ®Google Scholar
• Huang MA, Greenson JK, Chao C, One-year intense nutrional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005;100:1072-81
   PubMed Web of Science ®Google Scholar
• Nobili V, Alisi A, Raponi M. Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention. World J Gastroenterol 2009;15:6017-22
   PubMed Web of Science ®Google Scholar
• Kantartzis K, Thamer C, Peter A, High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 2009;58:1281-8
   PubMed Web of Science ®Google Scholar
• van der Heijden GJ, Wang ZJ, Chu ZD, A 12-week aerobic exercise program reduces hepatic fat accumulation and insuline resistance in obese, Hispanic adolescents. Obesity 2010;18:384-90
   PubMed Web of Science ®Google Scholar
• Manco M, Bottazzo G, Devito R, Nonalcoholic fatty liver disease in children. Am J Clin Nutr 2007;86:285-300
   PubMed Web of Science ®Google Scholar
• Toshimitsu K, Matsura B, Ohkubo I, Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition 2007;23:46-52
   PubMed Web of Science ®Google Scholar
• Abdelmalek MF, Suzuki A, Guy C, Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1961-71
   PubMed Web of Science ®Google Scholar
• Kirk E, Reeds DN, Finck BN, Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 2009;136:1552-60
   PubMed Web of Science ®Google Scholar
• Stein LL, Dong MH, Loomba R, Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: current status. Adv Ther 2009;26:893-907
   PubMed Web of Science ®Google Scholar
• Omer Z, Cetinkalp S, Akyildiz M, Efficacy of insulin-sensitizing agents in non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010;22:18-23
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Gentilcore E, Manini R, A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-90
   PubMed Web of Science ®Google Scholar
• Uygun A, Kadayifci A, Isik AT, Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004;19:537-44
   PubMed Web of Science ®Google Scholar
• Angelico F, Burattin M, Alessandri C, Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2007;1:CD005166
   Google Scholar
• Haukeland JW, Konopski Z, Eggesbø HB, Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009;44:853-60
   PubMed Web of Science ®Google Scholar
• Nobili V, Manco M, Ciampalini P, Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther 2008;30:1168-76
   PubMed Web of Science ®Google Scholar
• Ratziu V, Giral P, Jacqueminet S, Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008;135:100-10
   PubMed Web of Science ®Google Scholar
• Ratziu V, Charlotte F, Bernhardt C, Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010;51:445-53
   PubMed Web of Science ®Google Scholar
• Sanyal A, Chalasani N, Kowdley KV, Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-85
   PubMed Web of Science ®Google Scholar
• Belfort R, Harrison SA, Brown K, A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307
   PubMed Web of Science ®Google Scholar
• Aithal GP, Thomas JA, Kaye PV, Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176-84
   PubMed Web of Science ®Google Scholar
• Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease. Ther Adv Gastroenterol 2010;3:121-37
   PubMedGoogle Scholar
• Satapathy S, Sanyal A. Novel treatment modalities for nonalcoholic steatohepatitis. Trends Endocrinol Metab 2010;21:668-75
   PubMed Web of Science ®Google Scholar
• Hasegawa T, Yoneda M, Nakamura K, Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001;15:1667-72
   PubMed Web of Science ®Google Scholar
• Harrison SA, Torgerson S, Hayashi P, Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:2485-90
   PubMed Web of Science ®Google Scholar
• Miller ER. Meta-analysis, high dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46
   PubMed Web of Science ®Google Scholar
• Sesso HD. Vitamins E and C in the prevention of cardiovascular disease in men, the Physicians' Health Study II randomized controlled trial. JAMA 2008;300:2123-33
   PubMed Web of Science ®Google Scholar
• Kumar D, Tandon RK. Use of ursodeoxycholic acid in liver diseases. J Gastroenterol Hepatol 2001;16:3-14
   PubMed Web of Science ®Google Scholar
• Amaral JD, Viana RJS, Ramalho RM, Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res 2009;50:1721-34
   PubMed Web of Science ®Google Scholar
• Guma C, Viola L, Thome M, Ursodeoxycholic acid in the treatment of non-alcoholic steatohepatitis: results of prospective clinical controlled trial. Hepatology 1997;26:386A
   PubMed Web of Science ®Google Scholar
• Lindor KD, Kowdley KV, Heathcote EJ, Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39:770-8
   PubMed Web of Science ®Google Scholar
• Orlando R, Azzalini L, Orando S, Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007;1:CD005160
   Google Scholar
• Adams LA, Angulo P, Petz J, A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis. Hepatol Int 2010;4:628-33
   PubMed Web of Science ®Google Scholar
• Leuschner UFH, Lindenthal B, Herrmann G, High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo controlled trial. Hepatology 2010;52:472-9
   PubMed Web of Science ®Google Scholar
• Dufour JF, Oneta CM, Gonvers JJ, et al. randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006;4:1537-43
   PubMed Web of Science ®Google Scholar
• Balmer ML, Siegrist K, Zimmermann A, Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic seatohepatitis. Liver Int 2009;29:1184-8
   PubMed Web of Science ®Google Scholar
• Vajro P, Franzese A, Valerio G, Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 2000;136:739-43
   PubMed Web of Science ®Google Scholar
• Browning JD. Statins and hepatic steatosis: perspectives from the Dallas Hearth Study. Hepatology 2006;44:466-71
   PubMed Web of Science ®Google Scholar
• Hyogo H, Tazuma S, Arihiro K, Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008;57:1711-18
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
   PubMed Web of Science ®Google Scholar
• Argo CK, Loria P, Caldwell SH, Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 2008;48:662-9
   PubMed Web of Science ®Google Scholar
• Perelas A, Tsoulkani A, Perrea D. Effects of lipid-lowering drugs on adiponectin. Curr Vasc Pharmacol 2010;8:836-48
   PubMed Web of Science ®Google Scholar
• De Denus S, Spinler SA, Miller K, Statins and liver toxicity: a metaanalysis. Pharmacotherapy 2004;24:584-91
   PubMed Web of Science ®Google Scholar
• Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006;97:77C-81C
   PubMed Web of Science ®Google Scholar
• Antonopoulos S, Mikros S, Mylonopoulou M, Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006;184:233-4
   PubMed Web of Science ®Google Scholar
• Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006;23:1643-7
   PubMed Web of Science ®Google Scholar
• Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with non-alcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004;174:193-6
   PubMed Web of Science ®Google Scholar
• Fernandez-Miranda C, Perez-Carreras M, Colina F, A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 2008;40:200-5
   PubMedGoogle Scholar
• Fujita K, Yoneda M, Wada K, Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig Liver Dis 2008;40:200-5
   PubMedGoogle Scholar
• Yokohama S, Tokusashi Y, Nakamura K, Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol 2006;12:322-6
   PubMed Web of Science ®Google Scholar
• Yokohama S, Yoneda M, Haneda M, Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004;40:1222-5
   PubMed Web of Science ®Google Scholar
• Lichtenstein AH. Thematic review series: patients oriented research. Dietary fat, carbohydrate, and protein: effects on plasma lipoprotein patterns. J Lipid Res 2006;47:1661-7
   PubMed Web of Science ®Google Scholar
• Manco M, Calvani M, Mingrone G. Effects of dietary fatty acids on insulin sensitivity and secretion. Diabetes Obes Metab 2004;6:402-13
   PubMed Web of Science ®Google Scholar
• Flachs P, Rossmeisl M, Bryhn M, Cellular and molecular effects of n-3 polyunsatured fatty acid on adipose tissue biology and metabolism. Clin Sci 2009;116:1-6
   PubMed Web of Science ®Google Scholar
• Moussavi N, Gavino V, Receveur O. Could the quality of dietary fat, and not just its quantity, be related to risk of obesity? Obesity 2008;16:7-15
   PubMed Web of Science ®Google Scholar
• Klein-Platat C, Drai J, Oujaa M, Plasma fatty acid composition is associated with the metabolic syndrome and low-grade inflammation in overweight adolescents. Am J Clin Nutr 2005;82:1178-84
   PubMed Web of Science ®Google Scholar
• Spadaro L, Magliocco O, Spampinato D, Effects of n-3 polyunsatured fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008;40:194-9
   PubMedGoogle Scholar
• Nobili V, Bedogni G, Alisi A, Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-bind randomised controlled clinical trial. Arch Dis Child 2011;96:350-3
   PubMed Web of Science ®Google Scholar
• Sacks FM, Bray GA, Carey VJ, Comparison of weight-loss diets with different composition of fat, protein, and carbohydrates. N Engl J Med 2009;360:859-73
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA. Lifestyle modification as the primary treatment of NASH. Clin Liv Dis 2009;13:649-65
   PubMed Web of Science ®Google Scholar
• Bellentani S, Dalle Grave R, Suppini A, Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology 2008;47:746-54
   PubMed Web of Science ®Google Scholar
• Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2010;24:695-708
   PubMed Web of Science ®Google Scholar
• Loguercio C, De Simone T, Federico A, Gut-liver axis: a new point of attack to treat chronic liver damage. Hepatology 2009;97:2144-6
   Google Scholar
• Iacono A, Raso GM, Berni Canani R, Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem. 1 February 2011 [Epub ahead of print]; doi:10.1016/j.jnutbio.2010.10.002
   Web of Science ®Google Scholar
• Suzuki A, Lindor K, St Saver J, Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005;43:1060-6
   PubMed Web of Science ®Google Scholar
• Luyckx FH, Desaive C, Thiry A, Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998;22:222-6
   PubMed Web of Science ®Google Scholar